Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 16

1.

Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma.

Kushner BH, Kramer K, LaQuaglia MP, Modak S, Yataghene K, Cheung NK.

J Clin Oncol. 2004 Dec 15;22(24):4888-92.

PMID:
15611504
2.

Long-term follow up of high-dose chemotherapy with autologous stem cell rescue in adults with Ewing tumor.

Laurence V, Pierga JY, Barthier S, Babinet A, Alapetite C, Palangié T, de Pinieux G, Anract P, Pouillart P.

Am J Clin Oncol. 2005 Jun;28(3):301-9. Review.

PMID:
15923805
4.

Long-term follow-up status of patients with neuroblastoma after undergoing either aggressive surgery or chemotherapy--a single institutional study.

Kubota M, Yagi M, Kanada S, Okuyama N, Kinoshita Y, Yamazaki S, Asami K, Ogawa A, Watanabe T.

J Pediatr Surg. 2004 Sep;39(9):1328-32. Review.

PMID:
15359385
5.

A patient with granulocyte-colony stimulating factor-producing endometrial cancer who responded to high-dose cisplatin, cyclophosphamide and adriamycin.

Hada T, Mikami M, Kuwabara Y, Tanaka K, Ishikawa M, Komiyama S, Hirose T.

Eur J Obstet Gynecol Reprod Biol. 2004 Oct 15;116(2):242-3. Review. No abstract available.

PMID:
15358478
6.

Neuroblastoma with intracranial involvement: an ENSG Study.

Shaw PJ, Eden T.

Med Pediatr Oncol. 1992;20(2):149-55. Review.

PMID:
1734220
8.

Rapid COJEC Induction Therapy for High-risk Neuroblastoma Patients - Cochrane Review.

Peinemann F, van Dalen EC, Berthold F.

Klin Padiatr. 2016 Apr;228(3):130-4. doi: 10.1055/s-0042-103158. Epub 2016 Apr 4. Review.

PMID:
27043079
9.

[Organ preservation in the treatment of malignant solid tumors in children].

Saeki M, Nakano M, Kuroda T, Kinjo T, Torikai M, Tsunematsu Y, Kumagai M, Matsumoto Y, Masaki H, Kohda E.

Gan To Kagaku Ryoho. 1997 Apr;24(6):666-72. Review. Japanese.

PMID:
9126302
10.

Chemotherapeutic treatment of extensive optic pathway tumors in infants.

Kretschmar CS, Linggood RM.

J Neurooncol. 1991 Jun;10(3):263-70. Review.

PMID:
1895167
11.

Anti-GD2 monoclonal antibody immunotherapy: a promising strategy in the prevention of neuroblastoma relapse.

Raffaghello L, Marimpietri D, Pagnan G, Pastorino F, Cosimo E, Brignole C, Ponzoni M, Montaldo PG.

Cancer Lett. 2003 Jul 18;197(1-2):205-9. Review.

PMID:
12880983
12.

Contemporary therapeutic options for children with high risk neuroblastoma.

Sterba J.

Neoplasma. 2002;49(3):133-40. Review.

PMID:
12097996
13.

Unusual Differentiation to Pheochromocytoma-Like Cells in an Adrenal Neuroblastoma After Chemotherapy: A Case Report and Literature Review.

Tatekawa Y.

Fetal Pediatr Pathol. 2015;34(5):322-7. doi: 10.3109/15513815.2015.1068413. Epub 2015 Jul 24. Review.

PMID:
26207436
14.

Evidence for the efficacy of immunotherapy in children with high-risk neuroblastoma.

Szychot E, Peregud-Pogorzelski J, Wawryków P, Brodkiewicz A.

Postepy Hig Med Dosw (Online). 2016 Sep 28;70(0):1001-1004. Review.

15.

Neuroblastoma and treatment-related myelodysplasia/leukemia: the Memorial Sloan-Kettering experience and a literature review.

Kushner BH, Cheung NK, Kramer K, Heller G, Jhanwar SC.

J Clin Oncol. 1998 Dec;16(12):3880-9. Review.

PMID:
9850034
16.

Dinutuximab for maintenance therapy in pediatric neuroblastoma.

McGinty L, Kolesar J.

Am J Health Syst Pharm. 2017 Apr 15;74(8):563-567. doi: 10.2146/ajhp160228. Review.

PMID:
28389455

Supplemental Content

Support Center